Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality

TA-1887-treated or insulin-treated severely diabetic mice show enhanced survival and increased body weight but does not alter food intake or energy expenditure. a left: Changes in body weight in db/db mice fed a high-fat diet (HF) or comparable mice treated with saline (HF？+？saline) or with TA-1887(HF？+？TA) or insulin (HF？+？Ins) (n？=？20–30). right: AUC for body weight at indicated periods. b Food intake of each group at 13, 37, and 72 days (n？=？6). c Proportion of animals surviving 4 months (n？=？20–30). d Representative appearance of mice in indicated groups at day 80. e Energy expenditure (EE) after 9 weeks of each treatment, as determined by indirect calorimetry (n？=？6). f Volume of lean body mass, total fat, visceral fat (v fat) and subcutaneous fat (s fat), as measured by computed tomography (CT) after 3 months of each treatment (n？=？6). Values shown are means？±？SEM. *p？<？0.05, **p？<？0.01 versus HF, and # p？<？0.05, ## p？<？0.01 versus HF？+？saline, and ？？ p？<？0.01 versus HF？+？TA and ？？ p？<？0.01 versus HF？+？In